Sun Pharma Advanced Research Company Limited (SPARC.BO)
INR 143.0
(0.11%)
INR 143.0
(0.11%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -602.4 Million INR | -259.12% |
| 2022 | 671.99 Million INR | 536.85% |
| 2021 | 105.51 Million INR | -79.21% |
| 2020 | 507.62 Million INR | 143.75% |
| 2019 | -1.16 Billion INR | -617.07% |
| 2018 | 224.41 Million INR | 134.05% |
| 2017 | -659.1 Million INR | -442.75% |
| 2016 | 192.29 Million INR | -15.91% |
| 2015 | 228.69 Million INR | -33.89% |
| 2014 | 345.94 Million INR | -67.45% |
| 2013 | 1.06 Billion INR | 36.31% |
| 2012 | 779.73 Million INR | 261.64% |
| 2011 | 215.61 Million INR | -57.44% |
| 2010 | 506.65 Million INR | 84.01% |
| 2009 | 275.34 Million INR | -0.17% |
| 2008 | 275.81 Million INR | -9.87% |
| 2007 | 306.01 Million INR | 9968.14% |
| 2006 | -3.1 Million INR | 0.0% |
| 2005 | - INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -451.2 Million INR | -2.55% |
| 2024 Q2 | -370.9 Million INR | 17.8% |
| 2023 Q4 | -440 Million INR | -133.05% |
| 2023 Q2 | -35 Million INR | 80.77% |
| 2023 Q1 | -182 Million INR | -11.11% |
| 2023 FY | -1.06 Billion INR | -259.12% |
| 2023 Q3 | -188.8 Million INR | -439.43% |
| 2022 FY | 671.99 Million INR | 536.85% |
| 2022 Q1 | -103.1 Million INR | 29.52% |
| 2022 Q2 | -13.4 Million INR | 87.0% |
| 2022 Q3 | -35 Million INR | -161.19% |
| 2022 Q4 | -163.8 Million INR | -368.01% |
| 2021 FY | 105.51 Million INR | -79.21% |
| 2021 Q1 | -53.7 Million INR | 26.18% |
| 2021 Q3 | 362.8 Million INR | 1270.32% |
| 2021 Q2 | -31 Million INR | 42.27% |
| 2021 Q4 | -146.28 Million INR | -140.32% |
| 2020 FY | 507.62 Million INR | 143.75% |
| 2020 Q1 | 1.16 Billion INR | 338.71% |
| 2020 Q2 | -412.8 Million INR | -135.49% |
| 2020 Q3 | -176 Million INR | 57.36% |
| 2020 Q4 | -72.74 Million INR | 58.67% |
| 2019 FY | -1.16 Billion INR | -617.07% |
| 2019 Q1 | -369.9 Million INR | -234.11% |
| 2019 Q4 | -487.29 Million INR | -320.08% |
| 2019 Q3 | -116 Million INR | 39.24% |
| 2019 Q2 | -190.9 Million INR | 48.39% |
| 2018 Q1 | -167.3 Million INR | -567.32% |
| 2018 FY | 224.41 Million INR | 134.05% |
| 2018 Q4 | 275.81 Million INR | 209.89% |
| 2018 Q3 | -251 Million INR | -168.41% |
| 2018 Q2 | 366.9 Million INR | 319.31% |
| 2017 Q1 | -336.5 Million INR | -6571.15% |
| 2017 FY | -659.1 Million INR | -442.75% |
| 2017 Q4 | 35.8 Million INR | 120.85% |
| 2017 Q3 | -171.7 Million INR | 8.03% |
| 2017 Q2 | -186.7 Million INR | 44.52% |
| 2016 Q3 | -318.4 Million INR | -169.19% |
| 2016 FY | 192.29 Million INR | -15.91% |
| 2016 Q4 | 5.2 Million INR | 101.63% |
| 2016 Q2 | 460.2 Million INR | 882.65% |
| 2016 Q1 | -58.8 Million INR | -142.0% |
| 2015 Q3 | -194.7 Million INR | -306.91% |
| 2015 Q2 | 94.1 Million INR | -50.29% |
| 2015 Q4 | 140 Million INR | 171.91% |
| 2015 FY | 228.69 Million INR | -33.89% |
| 2015 Q1 | 189.3 Million INR | 59.24% |
| 2014 Q4 | 118.88 Million INR | 967.74% |
| 2014 FY | 345.94 Million INR | -67.45% |
| 2014 Q3 | -13.7 Million INR | -108.0% |
| 2014 Q2 | 171.3 Million INR | 152.65% |
| 2014 Q1 | 67.8 Million INR | -91.06% |
| 2013 Q4 | 758.61 Million INR | 51.94% |
| 2013 FY | 1.06 Billion INR | 36.31% |
| 2013 Q2 | 77.3 Million INR | -69.49% |
| 2013 Q1 | 253.4 Million INR | -74.97% |
| 2013 Q3 | 499.3 Million INR | 545.92% |
| 2012 Q1 | -40.5 Million INR | -110.93% |
| 2012 Q3 | -90.9 Million INR | 10.44% |
| 2012 Q4 | 1.01 Billion INR | 1213.9% |
| 2012 FY | 779.73 Million INR | 261.64% |
| 2012 Q2 | -101.5 Million INR | -150.62% |
| 2011 Q3 | -61.4 Million INR | 0.0% |
| 2011 FY | 215.61 Million INR | -57.44% |
| 2011 Q4 | 370.41 Million INR | 703.27% |
| 2010 FY | 506.65 Million INR | 84.01% |
| 2009 FY | 275.34 Million INR | -0.17% |
| 2008 FY | 275.81 Million INR | -9.87% |
| 2007 FY | 306.01 Million INR | 9968.14% |
| 2006 FY | -3.1 Million INR | 0.0% |
| 2005 FY | - INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 102.249% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 100.389% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 104.845% |
| Granules India Limited | 16.79 Billion INR | 103.586% |
| Indoco Remedies Limited | 6.04 Billion INR | 109.971% |
| Achyut Healthcare Limited | 4.86 Million INR | 12492.635% |
| Ajanta Pharma Limited | 21.06 Billion INR | 102.86% |
| Alkem Laboratories Limited | 52.29 Billion INR | 101.152% |
| Alpa Laboratories Limited | 188.89 Million INR | 418.911% |
| Brooks Laboratories Limited | 65.62 Million INR | 1018.022% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 109.681% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 140.93% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 116.301% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 100.368% |
| Eris Lifesciences Limited | 10.42 Billion INR | 105.777% |
| FDC Limited | 8.33 Billion INR | 107.228% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 100.869% |
| Gufic Biosciences Limited | 4.16 Billion INR | 114.454% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 109.725% |
| Ipca Laboratories Limited | 29.8 Billion INR | 102.021% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | 192.31% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | 412.57% |
| Lasa Supergenerics Limited | 121.02 Million INR | 597.733% |
| Laurus Labs Limited | 24.62 Billion INR | 102.447% |
| Lupin Limited | 123.71 Billion INR | 100.487% |
| Mankind Pharma Limited | 44.52 Billion INR | 101.353% |
| Medicamen Biotech Limited | 495.49 Million INR | 221.577% |
| Medico Remedies Limited | 262.14 Million INR | 329.8% |
| Megasoft Limited | 342.07 Million INR | 276.106% |
| NATCO Pharma Limited | 25.73 Billion INR | 102.341% |
| Piramal Pharma Limited | 24.47 Billion INR | 102.462% |
| RPG Life Sciences Limited | 2.48 Billion INR | 124.261% |
| Sigachi Industries Limited | 2 Billion INR | 130.086% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 100.233% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 114.61% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 163.923% |
| Unichem Laboratories Limited | 4.86 Billion INR | 112.383% |
| Wanbury Limited | 1.73 Billion INR | 134.808% |
| Windlas Biotech Limited | 1.33 Billion INR | 144.996% |
| ZIM Laboratories Limited | 1.26 Billion INR | 147.55% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 100.481% |
| Divi's Laboratories Limited | 32.44 Billion INR | 101.857% |
| Hester Biosciences Limited | 1.27 Billion INR | 147.298% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 110.42% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 138.702% |
| Bal Pharma Limited | 770.19 Million INR | 178.215% |
| Strides Pharma Science Limited | 14.38 Billion INR | 104.187% |
| Venus Remedies Limited | 2.18 Billion INR | 127.601% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 110.33% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 120.269% |
| Shilpa Medicare Limited | 3.54 Billion INR | 116.984% |
| Aarti Drugs Limited | 8.31 Billion INR | 107.244% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 113.151% |
| Suven Life Sciences Limited | -200.79 Million INR | -200.007% |
| Ind-Swift Limited | 2.17 Billion INR | 127.728% |
| Valiant Laboratories Limited | -60.66 Million INR | -893.021% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 102.654% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | 169.95% |
| Themis Medicare Limited | 1.5 Billion INR | 140.056% |
| Hikal Limited | 3.14 Billion INR | 119.166% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 101.288% |
| Sequent Scientific Limited | 2.97 Billion INR | 120.224% |
| Novartis India Limited | 1.32 Billion INR | 145.4% |
| Wockhardt Limited | 16.24 Billion INR | 103.709% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 103.067% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | 4231.813% |
| Neuland Laboratories Limited | 8.24 Billion INR | 107.304% |
| Morepen Laboratories Limited | 6.16 Billion INR | 109.777% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | 197.088% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | 185.617% |